For The Better

Subscriber growth may be abnormally slow, but the business model itself is plenty viable.

Customers in 400 U.S. cities will soon be able to order groceries on Uber.

It could be a sign of trouble for the streaming juggernaut.

The big bank reported a rare revenue miss, but that doesn’t tell the full story.

The short answer: They were impressive.

It’s one thing to buy Bitcoin as a near-term investment, but for retirement purposes, it becomes a lot more risky.

Which of these retail REITs is the better fit for your portfolio now?

On its recent earnings call, management said stablecoins could be the next big thing for the bank.

The push toward autonomous driving is far more than a one-company race.

This unlikely meme stock gives bulls and bears a lot to chew on.

Let’s clear the air about Intel’s struggles and ambitions.

This app for healthcare professionals could be an interesting investment.

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.

These companies pay hefty dividends and have big capital appreciation potential.

Which of these two high-growth chipmakers deserves your money?

There’s more to the Steam Deck than meets the eye. Here’s how it could impact its competitors.

Jazz Pharma is not the most popular drugmaker, but it is definitely worth a second look.

Yes, but it often doesn’t have much to do with revenue.

These fundamentally strong stocks are about to get even more attractive in the second half of 2021.

It’s easy to overlook these crucial Social Security facts.